Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

Takeshi Harada, MD PhD, Asuka Oda, Hiroto Ohguchi, MD PhD, Yohann Grondin, PhD, Hirofumi Tenshin, DDS, PhD, Masahiro Hiasa, DDS, PhD, Jumpei Teramachi, Masahiro Oura, MD, Kimiko Sogabe, MD, Shiro Fujii, MD PhD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Kumiko Kagawa, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD

Blood (2019) 134 (Supplement_1): 3111.

https://doi.org/10.1182/blood-2019-127679

Published: 2019

Journal Articles

The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis

Takeshi Harada, MD PhD, Asuka Oda, PhD, Yohann Grondin, PhD, Jumpei Teramachi, DDS, PhD, Ariunzaya Bat-Erdene, MD PhD, Masami Iwasa, MD, Masahiro Oura, MD, Shingen Nakamura, MD PhD, Kumiko Kagawa, MD PhD, Yasunobu Okamoto, MD, Kimiko Sogabe, MD, Shiro Fujii, MD, Hirokazu Miki, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD

Blood (2018) 132 (Supplement 1): 1939.

https://doi.org/10.1182/blood-2018-99-114086

Published: 2018

Journal Articles

Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

Shuji Ozaki, MD PhD, Takeshi Harada, MD PhD, Kengo Udaka, MD, Etsuko Sekimoto, MD PhD, Hironobu Shibata, MD PhD, Toshio Shigekiyo, MD PhD, Hikaru Yagi, MD, Yasunobu Okamoto, MD, Kimiko Sogabe, MD, Masahiro Oura, MD, Shiro Fujii, MD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Kumiko Kagawa, MD PhD, Masahiro Abe, MD PhD

Blood (2018) 132 (Supplement 1): 5577.

https://doi.org/10.1182/blood-2018-99-115818

Published: 2018

Journal Articles

Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma

Annamaria Gulla, MD, Teru Hideshima, MD PhD, Giada Bianchi, MD, Mariateresa Fulciniti, PhD, Mehmet K. Samur, PhD, Yu-Tzu Tai, PhD, Jun Qi, PhD, Takeshi Harada, MD PhD, Eugenio Morelli, MD, Nicola Amodio, PhD, Ruben D. Carrasco, MD PhD, Pierosandro Tagliaferri, MD, Nikhil C. Munshi, MD, Pierfrancesco Tassone, MD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 1140.

https://doi.org/10.1182/blood.V128.22.1140.1140

Published: 2016

Journal Articles

Targeting Ribonucleotide Reductase M1 and M2 in Multiple Myeloma

Morihiko Sagawa, MD PhD, Hiroto Ohguchi, MD PhD, Takeshi Harada, MD PhD, Mehmet K. Samur, PhD, Yu-Tzu Tai, PhD, Nikhil C Munshi, MD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 360.

https://doi.org/10.1182/blood.V128.22.360.360

Published: 2016

Journal Articles

HDAC3 Maintains DNMT1 through Dual Mechanisms in Multiple Myeloma

Takeshi Harada, MD PhD, Hiroto Ohguchi, MD PhD, Yohann Grondin, PhD, Shohei Kikuchi, MD PhD, Morihiko Sagawa, MD PhD, Yu-Tzu Tai, PhD, Ralph Mazitschek, PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 4472.

https://doi.org/10.1182/blood.V128.22.4472.4472

Published: 2016

Journal Articles

Expansion of γδT Cells By New Generation IMiDs and Their Cytotoxicity Against Myeloma Progenitors

Hirokazu Miki, MD PhD, Takeshi Harada, MD PhD, Qu Cui, MD PhD, Asuka Oda, Ariunzaya Bat-Erdene, Hirofumi Tenshin, DDS, Ryota Amachi, DDS, PhD, Ryohei Sumitani, MD, Munenori Uemura, MD, Mamiko Takahashi, MD, Masami Iwasa, MD, Shiro Fujii, MD, Jumpei Teramachi, DDS, PhD, Shingen Nakamura, MD PhD, Kumiko Kagawa, MD PhD, Shuji Ozaki, MD PhD, Masahiro Abe, MD PhD

Blood (2016) 128 (22): 2107.

https://doi.org/10.1182/blood.V128.22.2107.2107

Published: 2016

NARROW

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis

Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma

Targeting Ribonucleotide Reductase M1 and M2 in Multiple Myeloma

HDAC3 Maintains DNMT1 through Dual Mechanisms in Multiple Myeloma

Expansion of γδT Cells By New Generation IMiDs and Their Cytotoxicity Against Myeloma Progenitors

Email alerts

ASH Publications

American Society of Hematology

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis

Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice

Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma

Targeting Ribonucleotide Reductase M1 and M2 in Multiple Myeloma

HDAC3 Maintains DNMT1 through Dual Mechanisms in Multiple Myeloma

Expansion of γδT Cells By New Generation IMiDs and Their Cytotoxicity Against Myeloma Progenitors

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only